Pure Global
NCT05694260

A Phase 2 Clinical Study in Children With HeFH Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing

An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Bempedoic Acid in Pediatric Patients (6 to 17 Years of Age) With Heterozygous Familial Hypercholesterolemia
Esperion Therapeutics, Inc.·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Hypercholesterolemia
Drug/Device/Intervention
Bempedoic acid
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Esperion Therapeutics, Inc.
Location
Saint Louis,Salt Lake City,Chicoutimi,Hannover, Canada,Germany,United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Jan 12, 2023
End date
May 24, 2024
Enrollment
54 participants
Primary outcome

Observed pharmacokinetics - trough plasma concentration of ETC-1002,Model-based pharmacokinetics - AUC, ss,Model-based pharmacokinetics - Cavg, ss,Model-based pharmacokinetics - Cmax, ss

Summary

Multiple-dose study to measure PK, PD and safety of bempedoic acid in pediatric patients 6 to
 17 years of age with HeFH.

ICD-10 classifications
Pure hypercholesterolaemiaLipoprotein deficiencyHyperglycaemia, unspecifiedDisorders of lipoprotein metabolism and other lipidaemiasOther disorders of lipoprotein metabolism
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05694260
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05694260 through Pure Global AI's free database. This Phase 2 trial is sponsored by Esperion Therapeutics, Inc. and is currently Recruiting. The study focuses on Hypercholesterolemia. Target enrollment is 54 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.